Alessandra Fitzpatrick
Surgical · Bethesda, MDNPI 1346749900
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,729 of the $2,058 with a category attached, or 84.0%. It is spread thinly across 33 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $781, 2.1 times the $381 reported in 2021. Among surgical clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 82 payments — averaging $25.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$323
- AbbVie$227
- Novartis$187
- GSK$160
- Pharmacyclics LLC, An Abbvie Company$153
- AVEO Pharmaceuticals, Inc.$128
- plus $879 from 27 others
What the payments were for
- Food & beverage$1,72984%
- Education$32916%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 7 | $323 |
| AbbVie | 10 | $227 |
| Novartis | 8 | $187 |
| GSK | 5 | $160 |
| Pharmacyclics LLC, An Abbvie Company | 6 | $153 |
| AVEO Pharmaceuticals, Inc. | 3 | $128 |
| Pfizer | 3 | $74 |
| Pharmaessentia USA Corporation | 2 | $57 |
| Taiho Oncology, Inc. | 3 | $56 |
| Gilead | 3 | $53 |
| Deciphera Pharmaceuticals Inc. | 3 | $52 |
| Merck | 2 | $48 |
| Alnylam Pharmaceuticals Inc. | 3 | $48 |
| Beigene USA, Inc. | 2 | $45 |
| Daiichi Sankyo Inc. | 2 | $43 |
| AstraZeneca | 2 | $38 |
| Lilly USA, LLC | 2 | $30 |
| Ipsen Biopharmaceuticals, Inc | 1 | $26 |
| Genentech USA, Inc. | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $25 |
| Global Blood Therapeutics, Inc. | 1 | $24 |
| EMD Serono, Inc. | 1 | $24 |
| Novocure Inc. | 1 | $24 |
| Mirati Therapeutics, Inc. | 1 | $22 |
| Tersera Therapeutics LLC | 1 | $21 |
| Legend Biotech USA Inc. | 1 | $21 |
| Bristol Myers Squibb | 1 | $21 |
| Amgen | 1 | $20 |
| Accord Healthcare, Inc. | 1 | $18 |
| Incyte Corporation | 1 | $18 |
| Foundation Medicine, Inc. | 1 | $16 |
| Angiodynamics, Inc. | 1 | $16 |
| Sobi, Inc | 1 | $15 |
How this compares
$2,058 in reported general payments places this provider in the 90th percentile of 277 surgical providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 12 | $206,969 |
| NinlaroIxazomib Citrate | 11 | $145,565 |
| TykerbLapatinib Ditosylate | 13 | $107,682 |
| EliquisApixaban | 65 | $42,353 |
| XareltoRivaroxaban | 21 | $24,225 |
| SpsSodium Polystyrene Sulfon/Sorb | 11 | $449 |
| Tramadol Hcl | 24 | $419 |
| Anastrozole | 15 | $249 |
| Hydroxyurea | 14 | $184 |
| Gabapentin | 21 | $178 |
| Potassium Chloride | 12 | $35 |
| Allopurinol | 11 | $8 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $38 | $206,96912 claims |
| PfizerEliquis | $74 | $42,35365 claims |
| Johnson & JohnsonXarelto | $323 | $24,22521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 277 surgical providers in Maryland.
Other surgical in Bethesda
- Christina BulleyPotomac$39K
- Jenifer AbbottHavre de Grace$9K
- Jodie VogtmanHavre de Grace$9K
- Erika NigamBaltimore$8K
- Tara MorrisBaltimore$7K
- Megan BellGlen Burnie$7K
- Simone BeattieBaltimore$7K
- Marla MuhaGlen Burnie$5K
- Amanda PanfilCheverly$5K
- Virginia OrlovAnnapolis$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.